May 13, 2019
Positive Data From The Remetinostat Phase II Study in Basal Cell Carcinoma Presented at SID Annual meeting
May 07, 2019
Data From the Remetinostat Phase II Study in Basal Cell Carcinoma Patients to be Presented at the 2019 SID Annual Meeting
May 06, 2019
Safety and Efficacy Data From the MIV-711 Phase II Open Label Extension Study Presented at the OARSI World Congress
Apr 30, 2019
Data from the MIV-711 Phase II Program to be Presented at the OARSI World Congress
Apr 29, 2019
Medivir Appoints New CFO
Apr 10, 2019
Notice of Annual General Meeting of Medivir AB (publ)
Apr 08, 2019
Medivir's Annual Report for 2018 is Published
Mar 12, 2019
Medivir to Present at the Stockholm Corporate Finance Life Science Seminar on March 13
Feb 18, 2019
Lotta Ferm Appointed as Interim CFO at Medivir
Feb 14, 2019
Medivir Ab - Year End Report, January - December 2018
Dec 14, 2018
The Transformation Into a Company Focused on Clinical Development of Pharmaceuticals has now been Completed and Medivir Gives a Project Update
Nov 21, 2018
Medivir Nominates MIV-828 as a Candidate Drug for the Treatment of Hematological Malignancies
Oct 26, 2018
Medivir AB - Interim Report January - September 2018
Oct 19, 2018
New Data From the MIV-711 Phase II Program Will be Presented at the ACR Annual Meeting on October 21
Oct 17, 2018
Medivir Scales Back Research Costs to Focus on Clinical Development
Sep 10, 2018
Medivir Appoints Dr. Linda Basse as Chief Medical Officer
Aug 02, 2018
Investigator-initiated Phase II Clinical Study of Remetinostat Started in Patients With Basal Cell Carcinoma
Jul 27, 2018
MIV-711 Osteoarthritis Phase IIa Extension Study Outcomes Show Continuing Positive Effect on Joint Structure
Jul 25, 2018
Medivir AB - Interim Report January - June 2018
Jun 28, 2018
Medivir Announces Positive Top-line Results From the MIV-711 Osteoarthritis Phase IIa Extension Study